The role of p53 and autophagy in Dasatinib resistance of CLL lymphocytes

Leuk Res. 2011 Jan;35(1):32-3. doi: 10.1016/j.leukres.2010.07.007. Epub 2010 Jul 31.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Autophagy*
  • Dasatinib
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / pathology
  • Pyrimidines / therapeutic use*
  • Thiazoles / therapeutic use*
  • Tumor Suppressor Protein p53 / physiology*

Substances

  • Antineoplastic Agents
  • Pyrimidines
  • Thiazoles
  • Tumor Suppressor Protein p53
  • Dasatinib